Next Phase Newsletter

A USA-based life sciences venture capital and company formation firm with billions of dollars under management is currently investing out of their latest fund that closed last year. The firm will make equity investments of approximately $30–50 million over the lifetime of the company and can either lead investments or co-invest. The firm considers investment opportunities worldwide.

The firm invests primarily in therapeutics and invests broadly across different therapeutic areas and modalities. Areas of high interest include precision medicine approaches, gene therapy, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), ophthalmology, and rare diseases. The firm generally invests from preclinical (2–3 years pre-IND) through to Phase II, and prefers to invest in assets with good animal models and/or genetic evidence to support efficacy and target validation.

The firm generally invests in privately held companies and likes to work with experienced management teams who have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and we are therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a leading electronic solutions provider focuses on medical and pharmaceutical sectors, among other areas. The firm is actively looking to build and expand their pipeline and will focus on strategic investments in which the firm could bring significant value and those that supplement the firm’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but will look at Seed stage within the life science space. The firm usually invests around $1-5M initially and reserves capital for follow-on investment. The firm has a global footprint, with manufacturing plants throughout USA and Asia. The firm is open to global opportunities including those in rapidly growing markets such as China and India.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also looks at technology relating to other chronic illness, consumer health & wellness, and point of care diagnostic systems. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA. Recently, the firm has invested in a novel inhaled insulin delivery device.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital firm with headquarters in Asia and additional offices in USA, is backed by some large pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry.   Remiges Ventures only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC based in Western Europe invests opportunistically within the indications of nephrology, dermatology, urology, CNS/brain and orphan indications. The firm invests in companies from seed-Series A, up to 2M EUR. The firm is currently focused on European companies, but may consider companies based in North America as well.

Within the indications of interest, the firm is willing to consider companies in all sectors, therapeutics, medical devices, diagnostics and digital health. For therapeutic companies, the firm prefers the companies have some preclinical data, and be about a year from initiating clinical trials. For diagnostics companies, The firm prefers the companies be no more than 1 year from commercialization.

The firm can both lead or co-invest, and they may or may not take a board seat, depending on how they can help the company. The firm believes in promoting gender equality, and a large number of their investments are in female-led startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.